Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously.
Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes.
Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration.
Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings.
In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.